Soluble PD-L1 as an early marker of progressive disease on nivolumab

BACKGROUND: Soluble PD-L1 (sPD-L1) has been associated with worse prognosis in numerous solid tumors. We determined sPD-L1 levels before and during nivolumab treatment in two prospective clinical trials of metastatic clear cell renal cell carcinoma (RCC) and melanoma patients, and investigated its r...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahoney, Kathleen M, Ross-Macdonald, Petra, Yuan, Long, Song, Linan, Veras, Eliseo, Wind-Rotolo, Megan, McDermott, David F, Stephen Hodi, F, Choueiri, Toni K, Freeman, Gordon J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823247/
https://www.ncbi.nlm.nih.gov/pubmed/35131863
http://dx.doi.org/10.1136/jitc-2021-003527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823247/
https://www.ncbi.nlm.nih.gov/pubmed/35131863
http://dx.doi.org/10.1136/jitc-2021-003527

Ejemplares similares